Table 3 Sensitivity and specificity in detecting CIN2+ for Live and Static examinations
Swede Score | Sensitivity | Specificity | PPV | NPV |
|---|---|---|---|---|
Live (95% CI) | Live (95% CI) | Live (95% CI) | Live (95% CI) | |
Static (95% CI) | Static (95% CI) | Static (95% CI) | Static (95% CI) | |
10 | 0.0% (0.0–24.7%) | 98.8% (93.3–100.0%) | 86.0% (77.3–92.3%) | 0.0% (0.0–97.5%) |
0.0% (0.0–24.7%) | 100.0% (95.5–100.0%) | 86.2% (77.5–92.4%) | NaN% (0.0–100.0%) | |
9 | 15.4% (1.9–45.4%) | 98.8% (93.3–100.0%) | 87.9% (79.4–93.8%) | 66.7% (9.4–99.2%) |
0.0% (0.0–24.7%) | 100.0% (95.5–100.0%) | 86.2% (77.5–92.4%) | NaN% (0.0–100.0%) | |
8 | 30.8% (9.1–61.4%) | 97.5% (91.4–99.7%) | 89.8% (81.5–95.2%) | 66.7% (22.3–95.7%) |
15.4% (1.9–45.4%) | 95.1% (87.8–98.6%) | 87.5% (78.7–93.6%) | 33.3% (4.3–77.7%) | |
7 | 46.2% (19.2–74.9%) | 88.9% (80.0–94.8%) | 91.1% (82.6–96.4%) | 40.0% (16.3–67.7%) |
53.8% (25.1–80.8%) | 87.7% (78.5–93.9%) | 92.2% (83.8–97.1%) | 41.2% (18.4–67.1%) | |
6 | 53.8% (25.1–80.8%) | 77.8% (67.2–86.3%) | 91.3% (82.0–96.7%) | 28.0% (12.1–49.4%) |
69.2% (38.6–90.9%) | 67.9% (56.6–77.8%) | 93.2% (83.5–98.1%) | 25.7% (12.5–43.3%) | |
5 | 76.9% (46.2–95.0%) | 39.5% (28.8–51.0%) | 91.4% (76.9–98.2%) | 16.9% (8.4–29.0%) |
76.9% (46.2–95.0%) | 45.7% (34.6–57.1%) | 92.5% (79.6–98.4%) | 18.5% (9.3–31.4%) | |
4 | 76.9% (46.2–95.0%) | 37.0% (26.6–48.5%) | 90.9% (75.7–98.1%) | 16.4% (8.2–28.1%) |
84.6% (54.6–98.1%) | 30.9% (21.1–42.1%) | 92.6% (75.7–99.1%) | 16.4% (8.5–27.5%) | |
3 | 76.9% (46.2–95.0%) | 37.0% (26.6–48.5%) | 90.9% (75.7–98.1%) | 16.4% (8.2–28.1%) |
84.6% (54.6–98.1%) | 13.6% (7.0–23.0%) | 84.6% (54.6–98.1%) | 13.6% (7.0–23.0%) | |
2 | 76.9% (46.2–95.0%) | 33.3% (23.2–44.7%) | 90.0% (73.5–97.9%) | 15.6% (7.8–26.9%) |
92.3% (64.0–99.8%) | 8.6% (3.5–17.0%) | 87.5% (47.3–99.7%) | 14.0% (7.4–23.1%) | |
1 | 100.0% (75.3–100.0%) | 2.5% (0.3–8.6%) | 100.0% (15.8–100.0%) | 14.1% (7.7–23.0%) |
92.3% (64.0–99.8%) | 2.5% (0.3–8.6%) | 66.7% (9.4–99.2%) | 13.2% (7.0–21.9%) |